Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol.
作者信息
Harb Tarek, Ziogos Efthymios, Schär Michael, Brown Todd T, Lai Shenghan, Gerstenblith Gary, Hays Allison G, Leucker Thorsten M
机构信息
Division of Cardiology, Department of Medicine (T.H., E.Z., G.G., A.G.H., T.M.L.), Johns Hopkins University School of Medicine, Baltimore, MD.
Division of Magnetic Resonance Research, Department of Radiology (M.S.), Johns Hopkins University School of Medicine, Baltimore, MD.
出版信息
Circ Cardiovasc Imaging. 2023 Oct;16(10):e015693. doi: 10.1161/CIRCIMAGING.123.015693. Epub 2023 Sep 29.
Abstract
摘要
相似文献
1
Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol.在感染HIV的人群中，使用前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂后冠状动脉内皮功能的快速改善与脂蛋白（a）降低有关，而非低密度脂蛋白胆固醇（LDL-C）。
Circ Cardiovasc Imaging. 2023 Oct;16(10):e015693. doi: 10.1161/CIRCIMAGING.123.015693. Epub 2023 Sep 29.
2
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".尽管前蛋白转化酶枯草溶菌素9（PCSK9）水平较高，但HIV与丙型肝炎病毒合并感染的患者低密度脂蛋白胆固醇水平较低：一种明显的“PCSK9-脂质悖论”。
J Am Heart Assoc. 2016 Apr 29;5(5):e002683. doi: 10.1161/JAHA.115.002683.
3
Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol.冠心病患者血清 PCSK9 水平与内皮功能障碍相关，而与 LDL-C 无关。
J Am Heart Assoc. 2018 Oct 2;7(19):e009996. doi: 10.1161/JAHA.118.009996.
4
Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.抗逆转录病毒疗法对蛋白水解酶枯草溶菌素/克他命 9 的影响：重点关注脂质、炎症和免疫病毒学参数。
HIV Med. 2020 Sep;21(8):512-522. doi: 10.1111/hiv.12884. Epub 2020 Jun 4.
5
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.依洛尤单抗，一种 PCSK9 单克隆抗体，可迅速逆转患有 HIV 和血脂异常人群的冠状动脉内皮功能障碍。
J Am Heart Assoc. 2020 Jul 21;9(14):e016263. doi: 10.1161/JAHA.120.016263. Epub 2020 Jul 17.
6
Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.在一般人群中，血清前蛋白转化酶枯草溶菌素 9（PCSK9）与胰岛素抵抗、甘油三酯、脂蛋白（a）水平独立相关，但与低密度脂蛋白胆固醇水平无关。
J Atheroscler Thromb. 2021 Apr 1;28(4):329-337. doi: 10.5551/jat.56390. Epub 2020 Jul 4.
7
Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation.蛋白转化酶枯草溶菌素/克胰蛋白酶 9 水平随着 HIV/丙型肝炎病毒患者的丙型肝炎病毒治疗而下降，并与炎症相关。
AIDS. 2024 Mar 1;38(3):317-327. doi: 10.1097/QAD.0000000000003739. Epub 2023 Sep 29.
8
Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.与前蛋白转化酶枯草杆菌蛋白酶kexin 9抑制相关的低密度脂蛋白胆固醇水平降低不会增加出血性转化的风险。
Stroke. 2014 Oct;45(10):3086-8. doi: 10.1161/STROKEAHA.114.005958. Epub 2014 Aug 14.
9
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.载脂蛋白(a)降低后 LDL-C、估计真实 LDL-C、载脂蛋白 B-100 和 PCSK9 水平的关系。
采用反义寡核苷酸。
J Clin Lipidol. 2018 May-Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1.
10
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.衔接蛋白 1 是蛋白水解酶原转化酶枯草溶菌素/柯萨奇蛋白酶 9 的结合伴侣，并且对于蛋白水解酶原转化酶枯草溶菌素/柯萨奇蛋白酶 9 降解低密度脂蛋白受体是必需的。
Eur Heart J. 2020 Jan 7;41(2):239-252. doi: 10.1093/eurheartj/ehz566.
引用本文的文献
1
Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.脂蛋白（a）水平与临床决策：来自一家三级医疗机构的墨西哥队列研究数据。
Lipids Health Dis. 2025 May 26;24(1):192. doi: 10.1186/s12944-025-02610-w.
2
Lipoprotein(a) and Cardiovascular Disease in People Living With HIV: The Next Horizon.感染艾滋病毒者的脂蛋白(a)与心血管疾病：新的前沿领域。
J Am Heart Assoc. 2024 Dec 3;13(23):e039074. doi: 10.1161/JAHA.124.039074. Epub 2024 Nov 28.
3
Lipoprotein(a) Is Elevated and Inversely Related to Coronary Endothelial Function in People With HIV.脂蛋白(a)在HIV感染者中升高且与冠状动脉内皮功能呈负相关。
J Am Heart Assoc. 2024 Dec 3;13(23):e035975. doi: 10.1161/JAHA.124.035975. Epub 2024 Nov 22.
4
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.HIV 相关炎症及其对动脉粥样硬化性心血管疾病的影响。
Circ Res. 2024 May 24;134(11):1515-1545. doi: 10.1161/CIRCRESAHA.124.323891. Epub 2024 May 23.
5
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection.载脂蛋白(a)与 HIV 感染者和非感染者的冠状动脉周围炎症的相关性。
J Clin Lipidol. 2024 May-Jun;18(3):e430-e443. doi: 10.1016/j.jacl.2024.02.003. Epub 2024 Feb 15.
本文引用的文献
1
PCSK9 Inhibition and Oxidized Phospholipids.前蛋白转化酶枯草溶菌素9抑制与氧化磷脂
J Am Coll Cardiol. 2021 Sep 21;78(12):1288-1289. doi: 10.1016/j.jacc.2021.07.031.
2
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.依洛尤单抗，一种 PCSK9 单克隆抗体，可迅速逆转患有 HIV 和血脂异常人群的冠状动脉内皮功能障碍。
J Am Heart Assoc. 2020 Jul 21;9(14):e016263. doi: 10.1161/JAHA.120.016263. Epub 2020 Jul 17.
3
Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol.冠心病患者血清 PCSK9 水平与内皮功能障碍相关，而与 LDL-C 无关。
J Am Heart Assoc. 2018 Oct 2;7(19):e009996. doi: 10.1161/JAHA.118.009996.
4
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
5
Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease.
Circ Res. 2001 Jan 19;88(1):12-21. doi: 10.1161/01.res.88.1.12.
Zotero 插件